SRM/MRM Mass Spectrometry Assay for MGMT Protein Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, including traditional chemotherapeutic agents and targeted therapies, often fail to differentiate between cancer cells and normal cells, leading to unnecessary damage to healthy tissues, and there is a need for more precise methods to determine the effectiveness of treatments based on protein expression levels in cancer patients.
Innovation Solution
A quantitative proteomics-based assay using mass spectrometry to measure the levels of the 6-O-methylguanine-DNA methyltransferase (MGMT) protein in formalin-fixed cancer tissues, enabling the development of a targeted therapy approach by identifying specific peptides and their modifications for use in Selected Reaction Monitoring (SRM/MRM) assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional chemotherapeutic agents are used to kill rapidly dividing cells, then cancer cells are eliminated, but normal growing cells are also damaged
Solution Approach 1:
The patent segments the measurement process into multiple distinct steps: tissue fixation, protein extraction, proteolytic digestion, peptide purification, and mass spectrometric analysis. This segmentation allows for targeted measurement of MGMT protein levels in cancer tissues without affecting normal cells, enabling personalized therapy selection.
Solution Approach 2:
The patent uses mass spectrometry as an intermediary tool to indirectly measure MGMT protein levels. Instead of directly targeting cancer cells with therapy, the assay first quantifies protein expression levels, which then guides therapeutic agent selection. This intermediary measurement approach enables precise patient stratification.
2Object-affected harmful factors
If targeted therapies are used to selectively attack cancer cell proteins, then normal cells are protected, but treatment effectiveness depends on accurate protein expression measurement
Solution Approach 1:
The patent performs preliminary action by fixing cancer tissues in formalin and preserving them before analysis. This preliminary fixation step preserves protein expression levels at the time of biopsy, allowing for accurate baseline measurement of MGMT levels that will guide subsequent therapeutic decisions.
Solution Approach 2:
The patent employs parameter changes by using stable isotope-labeled internal standards with known concentrations. These isotopically labeled peptides serve as reference points that enable absolute quantification of MGMT protein levels through mass spectrometric ratio measurements, achieving high measurement precision.
3Adaptability or versatility
If mass spectrometry is used to quantify MGMT protein levels, then treatment decisions can be personalized, but the assay complexity increases
Solution Approach 1:
The patent extracts and isolates specific MGMT-containing peptides from complex cancer tissue protein mixtures through proteolytic digestion and selective purification. This extraction of target peptides from the complex biological matrix simplifies the subsequent mass spectrometric analysis by focusing measurement on specific diagnostic markers.
Solution Approach 2:
The patent creates synthetic copies of MGMT peptides that are identical to the native peptides but contain stable isotope labels. These copied peptides serve as internal standards that mirror the behavior of endogenous peptides during sample preparation and analysis, enabling accurate quantification while simplifying the assay design.
4Reliability
If formalin-fixed tissues are analyzed for MGMT levels, then clinically relevant samples can be tested, but protein degradation may occur
Solution Approach 1:
The patent applies beforehand cushioning by using formalin fixation to preserve cancer tissues immediately after biopsy. This preliminary preservation step protects proteins from degradation during storage and transport, maintaining MGMT protein integrity until the time of analysis.
Solution Approach 2:
The patent replaces mechanical or chemical protein extraction methods with mass spectrometric detection. Instead of attempting to extract and quantify intact MGMT protein (which may be unstable in fixed tissues), the method uses proteolytic digestion to convert proteins into more stable peptides that can be reliably measured by mass spectrometry.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides accurate and precise quantification of MGMT protein levels, aiding in cancer diagnosis, prognosis, and personalized treatment decisions by correlating protein expression with therapeutic agent effectiveness, thereby improving treatment outcomes.
Implementation Method 1
measuring by mass spectrometry the amount of the MGMT protein in a given protein preparation
Data Source
AI summary
The current disclosure provides methods for detecting and quantitating the 6-O-methylguanine-DNA methyltransferase protein (MGMT) directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed with formaldehyde containing agents/fixatives and may include formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and/or paraffin embedded. A protein sample is prepared from the biological sample and the MGMT protein is quantitated in the sample using SRM/MRM mass spectrometry by quantitating one or more fragment peptides.